Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham

Needham analyst Ami Fadia raised the price target on Definium Therapeutics Inc (NASDAQ: DFTX) to $50.00 (from $38.00) while maintaining a Buy rating.

The analyst commented: "DFTX de-risked a large market opportunity with the positive EMERGE data readout disclosed yesterday in MDD which not only demonstrated an improvement in pbo-adjusted reduction compared to Spravato but was also superior to the other psychedelics in development. The positive study provides additional confidence in the GAD studies (VOYAGE in early 3Q26, and PANORAMA in late 3Q26) expected in 3Q26 as ~25% of patients from the EMERGE study also had a GAD diagnosis. In terms of treatment experience, the average time for clearance was 5.8 hours with ~50% being ready clearance at hour 5. Overall, DT120 ODT demonstrated better than expected efficacy in MDD patients which supports the pivotal program and also provides additional confidence in GAD. We raise our PoS for MDD (60% from 25%) which increased our PT to $50."

You May Also Be Interested In

• Citi Upgrades Grupo Aeroportuario del Pacifico SAB de CV (GAPB:MM) (PAC) to Buy
• Citizens Financial Group (CFG) PT Raised to $85 at DA Davidson
• Permian Resources Corp (PR) PT Lowered to $24 at UBS Ahead of Q2 Earnings